Redox Proteins as Targets for Drugs Development Against Pathogens

Author(s): Daniela L. Catalano-Dupuy, Arleth Lopez-Rivero, Anabel Soldano, Eduardo A. Ceccarelli.

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 14 , 2013


Antimicrobial drug resistance in pathogens is an increasing human health problem. The rapid loss of effectiveness in antibiotics treatments and the accumulation of multi-resistant microbial strains are increasing worldwide threats. Moreover, several infectious diseases have been neglected for years and new antimicrobial treatments are lacking. In other cases, complexity of infectious organisms has exceeded the efforts to find new drugs to control them. Thus, strategies for the proper development of specific drugs are critically needed. Redox metabolism has already been proved to be a useful target for drug development. During the last years a significant number of electron carriers, enzymes, proteins and protein complexes have been studied and some of them were found to be essential for survival of several microbial pathogens. This review will focus on three major redox metabolic pathways which may provide promising strategies to fight against pathogens: the non-mevalonate pathway for isoprenoids biosynthesis, the iron metabolism and the iron-sulfur proteins. The common attractive link of all these processes is the plant-type ferredoxin-NADP+ reductase, an enzyme that participates in numerous electron transfer reactions and has no homologous enzyme in humans. Research in these redox pathways will open new perspectives for the rational design of drugs against infectious diseases.

Keywords: Isoprenoids biosynthesis, heme oxygenase, ferredoxin-NADP(H) reductase, ferredoxin, iron-sulfur clusters, iron-sulfur proteins, drug targets, pathogenicity

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [2594 - 2605]
Pages: 12
DOI: 10.2174/1381612811319140009
Price: $58

Article Metrics

PDF: 11